We have quantified the effects of the N-methyl-D-aspartate (NMDA) receptor antagonist (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) at rat recombinant Nmethyl-D-aspartate receptor (NR)1/NR2A and NR1/NR2B NMDA receptors expressed in Xenopus laevis oocytes. We observed no difference in the steady-state levels of inhibition produced by NVP-AAM077 when it was either preapplied or coapplied with glutamate. The IC 50 values for NVP-AAM077 acting at NR1/NR2A NMDA receptors were, as expected, dependent on the glutamate concentration used to evoke responses, being 31 Ϯ 2 nM (with glutamate at its EC 50 concentration) and 214 Ϯ 10 nM (at 10 times the EC 50 concentration). Schild analysis confirmed that the antagonism produced by NVP-AAM077 at NR1/NR2A NMDA receptors was competitive and gave an estimate of its equilibrium constant (K B ) of 15 Ϯ 2 nM. Furthermore, Schild analysis of an NMDA receptor carrying a threonine-to-alanine point mutation in the NR2A ligand binding site indicated that NVP-AAM077 still acted in a competitive manner but with its K B increased by around 15-fold. At NR1/ NR2B NMDA receptors, NVP-AAM077 displayed reduced potency. An IC 50 value of 215 Ϯ 13 nM was obtained in the presence of the EC 50 concentration of glutamate (1.5 M), whereas a value of 2.2 Ϯ 0.14 M was obtained with higher (15 M) glutamate concentrations. Schild analysis gave a K B for NVP-AAM077 at NR2B-containing receptors of 78 Ϯ 3 nM. Finally, using a kinetic scheme to model "synaptic-like" activation of NMDA receptors, we show that the difference in the equilibrium constants for NVP-AAM077 is not sufficient to discriminate between NR2A-containing or NR2B-containing NMDA receptors.The majority of NMDA receptors in the mammalian central nervous system are heteromeric assemblies made up of two NR1 and two NR2 subunits. NR1 subunits, which exist in one of eight splice variants, contain the binding site for the coagonist glycine, whereas four types of NR2 subunits exist (named NR2A-NR2D) and contain the binding site for glutamate (for reviews, see Dingledine et al., 1999;Erreger et al., 2004;Chen and Wyllie, 2006). By studying recombinant receptors of known subunit compositions, a defining "fingerprint" of their singlechannel properties, deactivation kinetics, sensitivity to block by ions, and pharmacological sensitivity to a variety of agonists and antagonists can be obtained (Monyer et al., 1992(Monyer et al., , 1994Ishii et al., 1993;Williams, 1993;Vicini et al., 1998;Erreger et al., 2004). Such information is invaluable when trying to identify the subunit composition of native NMDA receptors in central neurons. Unfortunately, it is rarely possible to undertake a series of biophysical-type experiments to identify the native NMDA receptor population; therefore, the development of selective antagonists that allow the unequivocal